Harnessing the power of cell-penetrating peptides: Activatable carriers for targeting systemic delivery of cancer therapeutics and imaging agents

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 5, Issue 1, 2013, Pages 31-48

  Macewan, Sarah R ^a   Chilkoti, Ashutosh ^a,b  

^a Duke University   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE TARGETING; CANCER CELLS; CANCER THERAPEUTICS; CELL-PENETRATING PEPTIDE; CELLULAR UPTAKE; CLINICAL UTILITY; ENHANCED PERMEABILITY AND RETENTION EFFECT; FUNCTIONALIZATIONS; HEALTHY TISSUES; IMAGING AGENT; NON-SPECIFICITY; PASSIVE TARGETING; SOLID TUMORS; SPECIFIC INTERACTION; TARGETED DELIVERY; TUMOR TARGETING;

DISEASES; PEPTIDES;

TUMORS;

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ARGININE; ASPARAGINASE; BACTENECIN; CELL PENETRATING PEPTIDE; DENDRIMER; DIAGNOSTIC AGENT; DOXORUBICIN; DRUG CARRIER; FLUORESCEIN; GADOLINIUM; GUANIDINE; HYDRAZONE DERIVATIVE; IODINE 125; LIPOSOME; LUTETIUM 177; MACROGOL; MATRIX METALLOPROTEINASE; MEMBRANE RECEPTOR; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OLIGOMER; PENETRATIN; POLYHISTIDINE; POLYLACTIC ACID; POLYMER; PROTEOGLYCAN; QUANTUM DOT; TECHNETIUM 99M; TRANSACTIVATOR PROTEIN;

AMINO ACID SUBSTITUTION; CELL VACUOLE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; ENDOCYTOSIS; EXTRACELLULAR MATRIX; HUMAN; INTERNALIZATION; MICELLE; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPERATURE;

ANIMALS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; HUMANS; MICE; MICELLES; NEOPLASMS;

EID: 84871652149     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1197     Document Type: Review

References (93)

1. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971, 28:1479-1499.
2. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 2011, 334:1129-1133.
3. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
4. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
5. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005, 338:284-293.
6. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994, 330:1260-1266.
7. Fink-Retter A, Gschwantler-Kaulich D, Hudelist G, Mueller R, Kubista E, Czerwenka K, Singer CF. Differential spatial expression and activation pattern of EGFR and HER2 in human breast cancer. Oncol Rep 2007, 18:299-304.
8. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008, 99:929-935.
9. Dexter DL, Leith JT. Tumor heterogeneity and drug resistance. J Clin Oncol 1986, 4:244-257.
10. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996, 271:18188-18193.
11. Kerkis A, Hayashi MA, Yamane T, Kerkis I. Properties of cell penetrating peptides (CPPs). IUBMB Life 2006, 58:7-13.
12. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55:1189-1193.
13. Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 2002, 41:14150-14157.
14. Khalil IA, Kogure K, Futaki S, Harashima H. Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. Int J Pharm 2008, 354:39-48.
15. Nakamura Y, Kogure K, Futaki S, Harashima H. Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release 2007, 119:360-367.
16. Al-Taei S, Penning NA, Simpson JC, Futaki S, Takeuchi T, Nakase I, Jones AT. Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjug Chem 2006, 17:90-100.
17. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 2000, 97:13003-13008.
18. Wender PA, Rothbard JB, Jessop TC, Kreider EL, Wylie BL. Oligocarbamate molecular transporters: design, synthesis, and biological evaluation of a new class of transporters for drug delivery. J Am Chem Soc 2002, 124:13382-13383.
19. Wender PA, Kreider E, Pelkey ET, Rothbard J, Vandeusen CL. Dendrimeric molecular transporters: synthesis and evaluation of tunable polyguanidino dendrimers that facilitate cellular uptake. Org Lett 2005, 7:4815-4818.
20. Vezenkov LL, Maynadier M, Hernandez JF, Averlant-Petit MC, Fabre O, Benedetti E, Garcia M, Martinez J, Amblard M. Noncationic dipeptide mimic oligomers as cell penetrating nonpeptides (CPNP). Bioconjug Chem 2010, 21:1850-1854.
21. Som A, Tezgel AO, Gabriel GJ, Tew GN. Self-activation in de novo designed mimics of cell-penetrating peptides. Angew Chem Int Ed Engl 2011, 50:6147-6150.
22. Hallbrink M, Kilk K, Elmquist A, Lundberg P, Lindgren M, Jiang Y, Pooga M, Soomets U, Langel U. Prediction of cell-penetrating peptides. Int J Peptide Res Therapeut 2005, 11:249-259.
23. Jones S, Holm T, Mager I, Langel U, Howl J. Characterization of bioactive cell penetrating peptides from human cytochrome c: protein mimicry and the development of a novel apoptogenic agent. Chem Biol 2010, 17:735-744.
24. Marks JR, Placone J, Hristova K, Wimley WC. Spontaneous membrane-translocating peptides by orthogonal high-throughput screening. J Am Chem Soc 2011, 133:8995-9004.
25. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 2004, 126:9506-9507.
26. Nakase I, Tadokoro A, Kawabata N, Takeuchi T, Katoh H, Hiramoto K, Negishi M, Nomizu M, Sugiura Y, Futaki S. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 2007, 46:492-501.
27. Dathe M, Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta 1999, 1462:71-87.
28. Henriques ST, Melo MN, Castanho MA. Cell-penetrating peptides and antimicrobial peptides: how different are they? Biochem J 2006, 399:1-7.
29. Kawamoto S, Takasu M, Miyakawa T, Morikawa R, Oda T, Futaki S, Nagao H. Inverted micelle formation of cell-penetrating peptide studied by coarse-grained simulation: importance of attractive force between cell-penetrating peptides and lipid head group. J Chem Phys 2011, 134:095103.
30. Henriques ST, Costa J, Castanho MA. Translocation of beta-galactosidase mediated by the cell-penetrating peptide pep-1 into lipid vesicles and human HeLa cells is driven by membrane electrostatic potential. Biochemistry 2005, 44:10189-10198.
31. Herce HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci U S A 2007, 104:20805-20810.
32. Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, Beltram F, Giacca M. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 2003, 278:34141-34149.
33. Mueller J, Kretzschmar I, Volkmer R, Boisguerin P. Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug Chem 2008, 19:2363-2374.
34. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005, 57:579-596.
35. Massodi I, Bidwell GL, 3rd, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release 2005, 108:396-408.
36. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res 2002, 19:744-754.
37. Chiu YL, Ali A, Chu CY, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004, 11:1165-1175.
38. Ifediba MA, Medarova Z, Ng SW, Yang J, Moore A. siRNA delivery to CNS cells using a membrane translocation peptide. Bioconjug Chem 2010, 21:803-806.
39. Choi Y, Kim K, Hong S, Kim H, Kwon YJ, Song R. Intracellular protein target detection by quantum dots optimized for live cell imaging. Bioconjug Chem 2011, 22:1576-1586.
40. Splith K, Hu W, Schatzschneider U, Gust R, Ott I, Onambele LA, Prokop A, Neundorf I. Protease-activatable organometal-Peptide bioconjugates with enhanced cytotoxicity on cancer cells. Bioconjug Chem 2010, 21:1288-1296.
41. Oh E, Delehanty JB, Sapsford KE, Susumu K, Goswami R, Blanco-Canosa JB, Dawson PE, Granek J, Shoff M, Zhang Q, et al. Cellular uptake and fate of PEGylated gold nanoparticles is dependent on both cell-penetration peptides and particle size. ACS Nano 2011, 5:6434-6448.
42. Qin Y, Chen H, Zhang Q, Wang X, Yuan W, Kuai R, Tang J, Zhang L, Zhang Z, Liu J, et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 2011, 420:304-312.
43. Sawant RR, Torchilin VP. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 2009, 374:114-118.
44. Kanazawa T, Taki H, Tanaka K, Takashima Y, Okada H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm Res 2011, 28:2130-2139.
45. Maiolo JR, Ferrer M, Ottinger EA. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta 2005, 1712:161-172.
46. Khalil IA, Kogure K, Futaki S, Harashima H. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 2006, 281:3544-3551.
47. Davidson TJ, Harel S, Arboleda VA, Prunell GF, Shelanski ML, Greene LA, Troy CM. Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 2004, 24:10040-10046.
48. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001, 19:1173-1176.
49. Flynn CR, Cheung-Flynn J, Smoke CC, Lowry D, Roberson R, Sheller MR, Brophy CM. Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci 2010, 99:3100-3121.
50. Brandt F, O'Connell C, Cazzaniga A, Waugh JM. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg 2010, 36(Suppl. 4):2111-2118.
51. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 2000, 6:1253-1257.
52. Miyaji Y, Walter S, Chen L, Kurihara A, Ishizuka T, Saito M, Kawai K, Okazaki O. Distribution of KAI-9803, a novel δ-protein kinase C inhibitor, after intravenous administration to rats. Drug Metab Dispos 2011, 39:1946-1953.
53. Liu JR, Zhao Y, Patzer A, Staak N, Boehm R, Deuschl G, Culman J, Bonny C, Herdegen T, Eschenfelder C. The c-Jun N-terminal kinase (JNK) inhibitor XG-102 enhances the neuroprotection of hyperbaric oxygen after cerebral ischaemia in adult rats. Neuropathol Appl Neurobiol 2010, 36:211-224.
54. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tsien RY. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009, 1:371-381.
55. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005, 5:786-795.
56. Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009, 27:5287-5297.
57. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, Torchilin VP. 'SMART' drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 2006, 17:943-949.
58. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009, 71:431-444.
59. Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using 'Smart' pH-sensitive TAT-modified pegylated liposomes. J Drug Target 2007, 15:538-545.
60. Koren E, Apte A, Jani A, Torchilin VP. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release 2012, 160:264-273.
61. Mok H, Bae KH, Ahn CH, Park TG. PEGylated and MMP-2 specifically dePEGylated quantum dots: comparative evaluation of cellular uptake. Langmuir 2009, 25:1645-1650.
62. Harris TJ, von Maltzahn G, Lord ME, Park JH, Agrawal A, Min DH, Sailor MJ, Bhatia SN. Protease-triggered unveiling of bioactive nanoparticles. Small 2008, 4:1307-1312.
63. Zhu L, Kate P, Torchilin VP. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 2012, 6:3491-3498.
64. Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 2007, 118:216-224.
65. Sethuraman VA, Lee MC, Bae YH. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm Res 2008, 25:657-666.
66. Kuai R, Yuan W, Qin Y, Chen H, Tang J, Yuan M, Zhang Z, He Q. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol Pharm 2010.
67. Kuai R, Yuan W, Li W, Qin Y, Tang J, Yuan M, Fu L, Ran R, Zhang Z, He Q. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Mol Pharm 2011, 8:2151-2161.
68. Lee ES, Gao Z, Kim D, Park K, Kwon IC, Bae YH. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Control Release 2008, 129:228-236.
69. Goun EA, Shinde R, Dehnert KW, Adams-Bond A, Wender PA, Contag CH, Franc BL. Intracellular cargo delivery by an octaarginine transporter adapted to target prostate cancer cells through cell surface protease activation. Bioconjug Chem 2006, 17:787-796.
70. Watkins GA, Jones EF, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, et al. Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem 2009, 17:653-659.
71. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A 2004, 101:17867-17872.
72. Olson ES, Aguilera TA, Jiang T, Ellies LG, Nguyen QT, Wong EH, Gross LA, Tsien RY. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) 2009, 1:382-393.
73. van Duijnhoven SM, Robillard MS, Nicolay K, Grull H. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation. J Nucl Med 2011, 52:279-286.
74. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010, 107:4311-4316.
75. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, Tsien RY. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A 2010, 107:4317-4322.
76. Levi J, Kothapalli SR, Ma TJ, Hartman K, Khuri-Yakub BT, Gambhir SS. Design, synthesis, and imaging of an activatable photoacoustic probe. J Am Chem Soc 2010, 132:11264-11269.
77. Li YT, Kwon YM, Spangrude GJ, Liang JF, Chung HS, Park YJ, Yang VC. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J Biomed Mater Res A 2009, 91:209-220.
78. Kwon YM, Li YT, Liang JF, Park YJ, Chang LC, Yang VC. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J Control Release 2008, 130:252-258.
79. Shamay Y, Adar L, Ashkenasy G, David A. Light induced drug delivery into cancer cells. Biomaterials 2011, 32:1377-1386.
80. Zhang W, Song J, Zhang B, Liu L, Wang K, Wang R. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells. Bioconjug Chem 2011, 22:1410-1415.
81. MacEwan SR, Chilkoti A. Digital switching of local arginine density in a genetically encoded self-assembled polypeptide nanoparticle controls cellular uptake. Nano Lett 2012, 12:3322-3328.
82. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010, 49:6288-6308.
83. Li SD, Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 2010, 145:178-181.
84. Choi JM, Ahn MH, Chae WJ, Jung YG, Park JC, Song HM, Kim YE, Shin JA, Park CS, Park JW, et al. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 2006, 12:574-579.
85. Lee ES, Na K, Bae YH. Super pH-sensitive multifunctional polymeric micelle. Nano Lett 2005, 5:325-329.
86. Huang Y, Park YS, Wang J, Moon C, Kwon YM, Chung HS, Park YJ, Yang VC. ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery. Curr Pharm Des 2010, 16:2369-2376.
87. Dreher MR, Simnick AJ, Fischer K, Smith RJ, Patel A, Schmidt M, Chilkoti A. Temperature triggered self-assembly of polypeptides into multivalent spherical micelles. J Am Chem Soc 2008, 130:687-694.
88. Roemer RB. Engineering aspects of hyperthermia therapy. Annu Rev Biomed Eng 1999, 1:347-376.
89. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hypertherm 2001, 17:1-18.
90. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 2011, 1816:232-246.
91. Lehto T, Kurrikoff K, Langel U. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin Drug Deliv 2012, 9:823-836.
92. Margus H, Padari K, Pooga M. Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 2012, 20:525-533.
93. Svensen N, Walton JGA, Bradley M. Peptides for cell-selective drug delivery. Trends Pharmacol Sci 2012, 33:186-192.